Quality statements

Quality statements

Statement 1 People with cystic fibrosis have the results of all assessments they have had during the past year reviewed annually by a specialist multidisciplinary team.

Statement 2 People with cystic fibrosis have individual rooms with en-suite facilities when admitted to hospital as inpatients.

Statement 3 People with cystic fibrosis who have chronic Pseudomonas aeruginosa infection have sustained treatment with an inhaled antibiotic.

Statement 4 People with cystic fibrosis who have clinical evidence of lung disease are prescribed rhDNase[1] as the first choice of mucoactive agent.

NICE has developed guidance and a quality standard on patient experience in adult NHS services (see the NICE Pathway on patient experience in adult NHS services), which should be considered alongside these quality statements.

Other quality standards that should be considered when commissioning or providing cystic fibrosis services include:

A full list of NICE quality standards is available from the quality standards topic library.



[1] At the time of publication (May 2018), rhDNase did not have a UK marketing authorisation for use in children under 5 years with cystic fibrosis for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's Prescribing guidance: prescribing unlicensed medicines for further information.